Legal Opinion
Eli Lilly and Co. v. Teva Parenteral Medicines, Inc.
Court of Appeals for the Federal Circuit
Decided August 24, 2012No. 2011-1561, 2011-1562, 2012-1037PublishedCited by 23 opinions
1Opinion of the Court
LOURIE, Circuit Judge.
Appellants Teva Parenteral Medicines, Inc., Barr Laboratories, Inc., and APP Pharmaceuticals, LLC appeal from the judgment of the United States District Court for the District of Delaware holding that U.S. Patent 5,344,932 (the “'932 patent”) is not invalid for obviousness-type double patenting. See Eli Lilly & Co. v. Teva Parenteral Meds. Inc., No. 08-335-GMS, 2011 U.S. Dist. LEXIS 83124, 2011 WL 3236037 (D.Del. July 28, 2011). We affirm.
BACKGROUND
This patent infringement dispute concerns applications filed by several generic pharmaceutical manufacturers seeking…
2Cases cited10 opinions
- Eurand, Inc. v. Mylan Pharmaceuticals Inc.Court of Appeals for the Federal Circuit · 2012
- Amgen Inc. v. F. Hoffmann-La Roche Ltd.Court of Appeals for the Federal Circuit · 2009
- In Re Paolo LongiCourt of Appeals for the Federal Circuit · 1985
- Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2008
- General Foods Corporation v. Studiengesellschaft Kohle MbhCourt of Appeals for the Federal Circuit · 1992
5 more not listed; retrieve them via the Exa API.
3Cited by23 opinions
- Eli Lilly and Company v. Teva Parenteral MedicinesCourt of Appeals for the Federal Circuit · 2017
- Eli Lilly and Company v. Hospira, Inc.Court of Appeals for the Federal Circuit · 2019
- AbbVie Inc. v. Mathilda & Terrance Kennedy Institute of Rheumatology TrustCourt of Appeals for the Federal Circuit · 2014
- Immunex Corporation v. Sandoz Inc.Court of Appeals for the Federal Circuit · 2020
- Novartis Pharmaceuticals Corp v. Breckenridge PharmaceuticalCourt of Appeals for the Federal Circuit · 2018
18 more not listed; retrieve them via the Exa API.